Ibezapolstat not checked

Acurx Pharmaceuticals Inc. · ACX-362E

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Clostridium Difficile Infection Recurrence
Main trialPhase 2
“Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).”In the company’s words, NCT07513285 on ClinicalTrials.gov
Other names
ACX-362E

Other drugs for Clostridium Difficile Infection Recurrence

All 16 drugs for Clostridium Difficile Infection Recurrence

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 29 Sep 2027 ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Phase 2Completed 3 Oct 2023 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Ibezapolstat

Following is part of Solo: you see every change to Ibezapolstat the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in